Frontiers in Cardiovascular Medicine

FEBRUARY 17, 2025

IntroductionSince TAVR was approved for lower-risk aortic stenosis (AS) patients, managing post-implantation conduction disturbances has become crucial, especially with self-expanding heart valves (SEV).

Pacemaker 52

Pacemaker Aortic Stenosis Aortic valve 52

DAIC

JUNE 7, 2024

milla1cf Fri, 06/07/2024 - 14:50 June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program , reinforcing the positive performance of the Evolut transcatheter aortic valve replacement (TAVR) System compared to surgical aortic valve replacement (SAVR) and other TAVR valves. Evolut vs. 10.6%

TAVR 111

TAVR Aortic valve Aortic Stenosis 111

CardiacWire

JANUARY 31, 2024

Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates. The post SAVR’s Value in the TAVR Era appeared first on Cardiac Wire.

TAVR 69

TAVR Aortic valve Bicuspid/Mitral Aortic 69

Cardiology Update

NOVEMBER 26, 2023

In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 3.5%, p=0.80) between the redo-TAVR and native-TAVR populations.

TAVR 52

TAVR Aortic valve Outcomes Aortic 52

Circulation: Cardiovascular Quality & Outcomes

DECEMBER 13, 2023

CONCLUSIONS:Daily step counts rapidly increased within the first 2 months post-TAVR. Increased physical activity was associated with a lower risk of 1-year mortality or rehospitalization after TAVR for patients with daily step counts below 5000.REGISTRATION:URL:[link] REGISTRATION:URL:[link] Unique identifier: NCT04454177.

TAVR 40

TAVR Aortic valve Aortic Outcomes 40

Circulation: Cardiovascular Interventions

OCTOBER 22, 2023

Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Exposure of interest was PVD. Primary outcome was all-cause mortality.

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. ET Murphy Ballroom 4 ACC.24 24 planners note that attendees can gain insights from key clinical trials presented at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103